FluBlok, a recombinant hemagglutinin influenza vaccine

Abstract  FluBlok, a recombinant trivalent hemagglutinin (HA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg‐based trivalent inactivated influenza vaccine (TIV) manufacturing process. FluBlok contains three times...

Descripción completa

Detalles Bibliográficos
Autores principales: Cox, Manon M.J., Patriarca, Peter A., Treanor, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2008
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634115/
https://www.ncbi.nlm.nih.gov/pubmed/19453397
http://dx.doi.org/10.1111/j.1750-2659.2008.00053.x
_version_ 1782399294900273152
author Cox, Manon M.J.
Patriarca, Peter A.
Treanor, John
author_facet Cox, Manon M.J.
Patriarca, Peter A.
Treanor, John
author_sort Cox, Manon M.J.
collection PubMed
description Abstract  FluBlok, a recombinant trivalent hemagglutinin (HA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg‐based trivalent inactivated influenza vaccine (TIV) manufacturing process. FluBlok contains three times more HA than TIV and does not contain egg‐protein or preservatives. This review discusses the four main clinical studies that were used to support licensure of FluBlok under the ‘Accelerated Approval’ mechanism in the United States.
format Online
Article
Text
id pubmed-4634115
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-46341152015-11-27 FluBlok, a recombinant hemagglutinin influenza vaccine Cox, Manon M.J. Patriarca, Peter A. Treanor, John Influenza Other Respir Viruses Reviews Abstract  FluBlok, a recombinant trivalent hemagglutinin (HA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg‐based trivalent inactivated influenza vaccine (TIV) manufacturing process. FluBlok contains three times more HA than TIV and does not contain egg‐protein or preservatives. This review discusses the four main clinical studies that were used to support licensure of FluBlok under the ‘Accelerated Approval’ mechanism in the United States. Blackwell Publishing Ltd 2008-12-08 2008-11 /pmc/articles/PMC4634115/ /pubmed/19453397 http://dx.doi.org/10.1111/j.1750-2659.2008.00053.x Text en © 2008 Protein Sciences Corp. Journal Compilation © 2008 Blackwell Publishing Ltd
spellingShingle Reviews
Cox, Manon M.J.
Patriarca, Peter A.
Treanor, John
FluBlok, a recombinant hemagglutinin influenza vaccine
title FluBlok, a recombinant hemagglutinin influenza vaccine
title_full FluBlok, a recombinant hemagglutinin influenza vaccine
title_fullStr FluBlok, a recombinant hemagglutinin influenza vaccine
title_full_unstemmed FluBlok, a recombinant hemagglutinin influenza vaccine
title_short FluBlok, a recombinant hemagglutinin influenza vaccine
title_sort flublok, a recombinant hemagglutinin influenza vaccine
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634115/
https://www.ncbi.nlm.nih.gov/pubmed/19453397
http://dx.doi.org/10.1111/j.1750-2659.2008.00053.x
work_keys_str_mv AT coxmanonmj flublokarecombinanthemagglutinininfluenzavaccine
AT patriarcapetera flublokarecombinanthemagglutinininfluenzavaccine
AT treanorjohn flublokarecombinanthemagglutinininfluenzavaccine

Ejemplares similares